

INDEX

I-1

	<u>page(s)</u>
"8" and Primary Site Code	71
"9" and Primary Site Code	71, 73
abbreviations, acceptable	Appendix C
abbreviations for City/Town at Diagnosis	56
abbreviations, postal	48, 50, Appendix F
Abstract, paper, Massachusetts Cancer Registry	4
abstractor of case (Abstracted By)	38
"abuts" and Summary Stage	133
Accession Number	7, 31
Accession Number and diagnosis year	31
Accession Number and Year First Seen for This Primary	36
Address at Diagnosis	7, 46-51
address, for college student	47
address, current	182
address, foreign	49-51, 182
address, military base	47
adenocarcinoma in adenomatous polyposis coli	15-16
adenocarcinoma in multiple adenomatous polyps	15-16
"adherent" and Summary Stage	133
adjuvant chemotherapy	169
adrenocorticosteroids	173
Age at Diagnosis	7, 44
Age , patient's	7, 44
age/diagnosis combination, unusual, and Comments/Narrative Remarks	44, 182
AIN, case reportability	9, 85
AJCC "grade" code	89
AJCC staging	109-130
AJCC staging books as references	5
"aka" name	42
Alias	42
"also known as" name	42
anal intraepithelial neoplasia, case reportability	9, 85
analytic case and Class of Case	96
ancillary drugs	171, 176, 178
antihormone therapy	173
"apparently" and case reportability	10

INDEX

I-2

	<u>page(s)</u>
"apparently" and Summary Stage	133
"appears" and case reportability	10
"appears" and Summary Stage	133
"approaching" and Summary Stage	133
"approximates" and Summary Stage	133
"areas of" and Histologic Type Code	83
aspiration of cells and DX/Stg/Pall Proc	154
aspiration of node and Scope of Regional Lymph Node Surgery	160
aspiration, bone marrow, and Diagnostic Confirmation	106
aspiration, fine needle, and Diagnostic Confirmation	106
aspirin as Other Cancer-Directed Treatment	179
astrocytomas and Behavior	28, 86
at this facility, treatment, fields	151
aTNM.....	110
"attached" and Summary Stage	133
autopsy, histology and Diagnostic Confirmation	106
autopsy, cancer found at.....	3
autopsy case and Date of First Contact	39
autopsy case and Date of Diagnosis	94
autopsy case and Reason for No Surgery	165
autopsy case and treatment dates	151, 152
autopsy case and Type of Reporting Source	108
autopsy, gross and Diagnostic Confirmation	107
autopsy prefix and TNM staging, not coded	110
"autumn" and Date of Diagnosis	95
basal cell carcinomas, as non-reportable cases	9, 85
beam radiation, types of.....	166
Behavior and single-vs.-multiple primaries	16, 18, 82-84
Behavior and staging differences	88
Behavior Code	84-88
Behavior Code and case reportability.....	9, 11, 85
benign cases and Grade	91, 92
benign cases, reportability	9, 11, 85
benign tumor, Sequence Number	34
bilateral involvement and single-vs.-multiple primaries	19
bilateral lymph node involvement and Summary Stage	137
bilateral ovarian primary, Laterality	19, 76

INDEX

I-3

	<u>page(s)</u>
bilateral retinoblastoma, Laterality	19, 76
bilateral tumors and TNM staging.....	109
bioelectromagnetic treatment	178
biological response modifier therapy.....	176-177
biopsy and Diagnostic Confirmation	106
biopsy, bone marrow, and Diagnostic Confirmation	106
biopsy, excisional, and Surgery	153, 154, 156
biopsy, excisional and Tumor Size	100
biopsy, incisional, and DX/Stg/Pall Proc	153
biopsy, negative and positive cytology, case reportability	29
biopsy, NOS and DX/Stg/Pall Proc	153
Birth Date	7, 43, 44
Birth Date and changes/case deletion.....	4
Birthplace	45, Appendix A
Birthplace and Race	55-59
Birthplace and Spanish/Hispanic Origin	60
bladder cases, and single-vs-multiple primaries	18
bladder, transurethral resection and Tumor Size	104
blood transfusion as Other Cancer-Directed Treatment	179
Bloom-Richardson grading and Grade Code	93
bone marrow aspiration and Diagnostic Confirmation	106
bone marrow biopsy and Diagnostic Confirmation	106
bone marrow transplant.....	176
borderline malignancy, and Sequence Number	34
borderline malignancy, case reportability	9, 11, 85
Bowen disease and Behavior Code	87
BR grading and Grade Code	93
brachytherapy, radioactive implants	166
brain primary and Regional Nodes Examined	142
brain primary and Number of Regional Nodes Removed	162
brain primary and Regional Nodes Positive	144
brain tumors and Grade Code	92
brain tumors, reportability.....	9, 11-13, 85
breast cancer and combination Histology codes.....	19
breast cancer and Grade Code	93
breast cancer and Tumor Size	103
breast cancer cases and single-vs-multiple primaries.....	19-20

INDEX

I-4

	<u>page(s)</u>
Breslow measurement (thickness) and Tumor Size	105
BRM therapy	176-177
business/industry	66, 69
bypass and DX/Stg/Pall Proc	153
"cancer diagnosis"	10
cancer-directed Surgery	156-163, Appendix D
cancer-directed Surgery and endocrine surgery.....	174
cancer-directed Surgery and radiation therapy	168
cancer-directed Surgery , none, and TNM staging.....	110
"cancer-directed treatment" defined.....	150
"cannot be excluded" and Summary Stage	133
"cannot be ruled out" and case reportability	10
"cannot be ruled out" and Summary Stage	133
carcinoma <i>in situ</i> , lobular	11
carcinoma <i>in situ</i> of cervix uteri, case reportability.....	9, 85
carcinoma, inflammatory, and Tumor Size	103
carcinoma, squamous cell, microinvasive, and Behavior Code	88
carcinoma, squamous cell, microinvasive, and Summary Stage	135
carcinomas, basal cell, as non-reportable cases	9, 85
carcinomas, ductal and lobular, and Primary Site Code	73
carcinomas, papillary, of skin as non-reportable cases	9, 85
carcinomas, squamous cell, of skin as non-reportable cases	9, 85
Case Completed, Date	183
Case Report Exported, Date	183
Case Report Received, Date	183
case submission to the Massachusetts Cancer Registry	4
casefinding	2
CDC/NPCR grant to Massachusetts Cancer Registry	1
cell aspiration and DX/Stg/Pall Proc	154
Cell Origin (Cell Type) Immunophenotype) Code	89, 91
Central Sequence Number	35
central nervous system cases, reportability	9, 11-13, 85
cervix, carcinoma <i>in situ</i> , case reportability.....	9, 11, 85
cervix, intraepithelial neoplasia of, case reportability	9, 11, 85
changes to reported cases	4
charity case, Primary Payer at Diagnosis	37
Chemotherapy	169-172

INDEX

I-5

	<u>page(s)</u>
Chemotherapy , adjuvant	169
Chemotherapy agents	170
Chemotherapy -- At This Facility	172
Chemotherapy , concurrent	169
Chemotherapy -- Date Started	172
Chemotherapy drugs	170
Chemotherapy -- Narrative	172
Chemotherapy -- Narrative and ancillary drug	172
Chemotherapy , neoadjuvant	169
Chemotherapy protocol number	169, 172
Chemotherapy replacement agents	170
Chemotherapy subsequent to first-course treatment	170
Chemotherapy -- Summary	172
Chemotherapy with Prednisone	171, 173
child, recording occupation/industry for	67
CIN III, case reportability	9, 85
City/Town at Diagnosis	49
Class 3 case and Address at Diagnosis	47
Class 3 case reporting	3, 7, 97
Class 4 case and Address at Diagnosis	47
Class 4 case reporting	3, 7, 97
Class 5 case and Date of Diagnosis	95
Class 5 case reporting	3, 7, 97
Class 6 case reporting	3, 7, 30, 96, 97
Class 9 case reporting	3, 7, 97
Class of Case	96-97
Class of Case and Class 6's	7, 96, 97
Class of Case and reportability	3, 7, 30, 95-96
clinical M Element	116-118
clinical N Element	114-115
clinical Stage Grouping	119-120
clinical staging, TNM	109, 110, 111-120
clinical T Element	111-113
clinical trial, double-blind, therapy	178, 180
clitoris, skin of, case reportability	9, 85
cM	116-118
cN	114-115

INDEX

I-6

	<u>page(s)</u>
code priority, surgery of primary site	157
coding pre-2001 cases.....	i
colon cancer and Tumor Size	103
colon polyps and single-vs-multiple primaries	15-16
combination codes, histology	19, 82, 84
combination, site/histology, and Comments/Narrative Remarks	75, 182
Comments/Narrative Remarks	35, 43, 47, 75, 78, 159, 182
Comments/Narrative Remarks and address notes.....	47
Comments/Narrative Remarks and estimated dates	43, 95
Comments/Narrative Remarks and previous primaries	35
Comments/Narrative Remarks and unusual name/gender	51
Comments/Narrative Remarks and unusual Site/Histology	75, 78, 94
"comparable" and case reportability	10
"compatible with" and case reportability	10
"compatible with" and Summary Stage	133
computer vendor, name.....	183
confidentiality.....	2
Confirmation, Diagnostic	106-107
confirmation of diagnosis, and case reportability.....	10
confirmation, pathologic, and case reportability	10
conization and Diagnostic Confirmation	106
"consistent with" and case reportability	10
"consistent with" and Summary Stage	133
consultation-only cases, reportability	29-30
"contiguous" and Summary Stage	133
"continuous with" and Summary Stage	133
Conversion Flag, ICD-O-2 to ICD-O-3	88
COPP + Prednisone.....	171, 173
craniopharyngeal duct and case reportability.....	9, 85
cStage Grouping	119-120
cT.....	111-113
CT scan and Diagnostic Confirmation	107
cTNM	109, 111-118
curettage and Diagnostic Confirmation	106
cystadenomas, ovarian and case reportability	28
cytology and Diagnostic Confirmation	106
cytology report and Grade/Differentiation/Immunophenotype Code	90

INDEX

I-7

	<u>page(s)</u>
cytology report and negative biopsy, case reportability.....	29
cytology report, "suspicious", and case reportability.....	10
D&C and DX/Stg/Pall Proc	153
<i>Data Standards</i> , NAACCR, as reference.....	5
Date Case Completed	183
Date Case Report Exported	183
Date of Birth	7, 43, 44
Date, Chemotherapy Started	172
Date, Hormone Therapy Started	175
Date, Immunotherapy Started	177
Date, DX/Stg/Pall Proc Started	155
date of death and Date of Diagnosis for autopsy case.....	94
date of death as Date of First Contact	39
date of death as Date of Last Contact	181
Date of Diagnosis	7, 28, 94-95
Date of Diagnosis and case coding	28
Date of Diagnosis and changes/case deletion	4
Date of Diagnosis and therapy before definitive diagnosis	95
Date of Diagnosis estimated.....	i, 95
Date of Diagnosis unknown and coding rules	i, 130
Date of First Contact	39
Date of First Contact and case coding.....	28
Date of First-Course Treatment	152
Date of Last Contact	7, 181
Date, Other Therapy Started	180
Date, Radiation Therapy Started	168
Date, Surgery Started	159
dates, treatment started.....	151
death date and Date of Diagnosis for autopsy case	94
death date as Date of First Contact for autopsy case.....	39
death date as Date of Last Contact	181
Death, Place of	182, Appendix A
Decadron.....	173
"default" Primary Site Code	72
deleting a reported case.....	4
Diagnosis Date	7, 94-95
diagnosis of cancer	10

INDEX

I-8

	<u>page(s)</u>
diagnosis year and Age at Diagnosis	44
diagnosis year and case coding.....	28
Diagnostic Confirmation	106-107
Diagnostic Imaging Narrative	146
Diagnostic Procedures Narratives	145-147
Diagnostic, Staging, or Palliative Procedures	153-155, 156, 159
Diagnostic, Staging, or Palliative Procedures -- At This Facility	155
Diagnostic, Staging, or Palliative Procedures -- Date Started	155
Diagnostic, Staging, or Palliative Procedures -- Summary	154
Differentiation Code	89-93
"diffuse" and Tumor Size	103
dilation and curettage, and DX/Stg/Pall Proc	153
"direct extension" and Summary Stage	133
direct visualization and Diagnostic Confirmation	107
diskette, reporting cases on	4, 5, 29
dissection, neck, and Scope of Regional Lymph Node Surgery	160
distant Summary Stage	137-138
double-blind clinical trial therapy	178
doubtful diagnosis and Comments/Narrative Remarks	75, 78, 94
duct carcinoma and Paget disease of breast.....	20
duct, lobular and other carcinomas of breast.....	19
duct and lobular carcinomas of breast, and Primary Site Code	73
DX/Stg/Pall Proc -- At This Facility	155
DX/Stg/Pall Proc -- Date Started	155
DX/Stg/Pall Proc -- Summary	154
DX/Stg/Pall Proc and Surgery -- Narrative	155
"E", "E+S" lymphoma suffixes, and TNM staging, not collected.....	120, 129
"effaces" and Summary Stage	133
"elements of" and Histologic Type Code	83
Elston-Ellis grading and Grade Code	93
embolization, tumor.....	178
en bloc resection of primary and regional tissues, and Surgery of Primary Site	157, 163
"encases" and Summary Stage	133
"encompasses" and Summary Stage	133
"encroaching upon" and Summary Stage	133
endocrine gland removal and DX/Stg/Pall Proc	153
endocrine radiation	166, 174

INDEX

I-9

	<u>page(s)</u>
endocrine surgery.....	153, 174
endocrine therapy.....	173-175
endoscopy and Diagnostic Confirmation	107
endoscopy Narrative	146
"enlarged", lymph nodes, and Summary Stage	137
"entrapped" and Summary Stage	133
EOD--Extension	144
EOD--Extension Prostate Pathology	144
EOD--Tumor Size	100-105
epithelial carcinomas of skin as non-reportable cases.....	9, 85
Epogen	176, 178
"equivocal" and case reportability.....	10
"equivocal" and Summary Stage	133
erythroplasia, Queyrat, and Behavior Code	87
esophagus, cancer of, and Tumor Size	103
estimating Birth Date	43
estimating Date of Diagnosis	95
estimating treatment start dates	151, 152
ethnicity and Spanish/Hispanic Origin	60-64
excisional biopsy and Surgery	153, 154, 156, 157
excisional biopsy and Tumor Size	100
experimental treatment	178
exploratory and DX/Stg/Pall Proc	153
Exported Date, of Case Report	183
"extension into / onto / out onto / to" and Summary Stage	133
"extension to" and Summary Stage	133
"extension to without invasion/ involvement" and Summary Stage	133
Facility Code	7, 31, 32
Facility Code and diskette reporting	31
Facility Name	31
Facility Name and diskette reporting	31
"fall" and Date of Diagnosis	95
familial polyposis and Primary Site Code	15-16, 73
familial polyposis and Tumor Size	103
familial polyposis, colon polyps, and single-vs-multiple primaries	15-16
"favors" and case reportability.....	10
"features of" and Summary Stage	133

INDEX

I-10

	<u>page(s)</u>
FIN (Facility Identification Number).....	31, 32
fine needle aspiration and Diagnostic Confirmation	106
first course of therapy and Regional Nodes Examined	142
first course of therapy and Regional Nodes Positive	143
"first course of therapy / treatment" defined.....	149-150
first course of treatment and time periods	149-150
First Course of Treatment, Date Started	152
First Name, Patient	7, 41
First Name/Sex , unusual.....	51
"fixation / fixed" and Summary Stage	133
"fixed", lymph nodes, and Summary Stage	133
Fletcher after-loader / Fletcher suit, radiation therapy.....	166
fluid removal, malignant, and DX/Stg/Pall Proc	153
FNA and Diagnostic Confirmation	106
follow-up and Date of Last Contact	181
foreign patient address.....	47-51
frozen section and Diagnostic Confirmation	106
gender, patient's.....	51
generation identifiers (Junior, Senior, III).....	40
genital sites, skin of, case reportability.....	9, 85
gland, endocrine, removal, and DX/Stg/Pall Proc	153
Gleason's Pattern / Gleason's Score and Grade Code	93
Grade Code	7, 89-93
grade, nuclear	89
Grade terminology	89, 91, 92-93
granulocyte colony stimulating factor	178
hematologic diseases and single-vs-multiple primaries.....	insert, 21-27
hematopoietic diseases and Other Cancer-Directed Treatment	179
hematopoietic neoplasm and Tumor Size	104
Herceptin.....	178
Heyman capsule, radiation therapy	166
"high grade" lymphoma and Grade Code	89, 91
Hispanic Origin	60-64
Hispanic surname	60-64
Histologic Type Code	7, 79-84
"histologic type difference" for single-vs-multiple primaries.....	16
Histology and case reportability.....	9, 11, 85

INDEX

I-11

	<u>page(s)</u>
histology code, "NOS"	18, 22, 82, 83, 84
histology codes, combination	19-20, 79, 82, 83
Histology/Behavior/Grade Narrative	94
histology/site combination, unusual, and Comments/Narrative Remarks	75, 78, 182
histopathology report Narrative	147
HMO, Primary Payer at Diagnosis	37
Hodgkin lymphoma and Tumor Size	104
homeless patient, address	47
homeopathic treatment	178
hormonal (endocrine) radiation	174
hormonal surgery (endocrine surgery)	174
hormone replacement	174
hormone therapy	153, 171, 173-175
Hormone Therapy -- At This Facility	175
Hormone Therapy -- Date Started	175
Hormone Therapy -- Narrative	175
Hormone Therapy -- Summary	175
Hospital Sequence Number	33-35
Hutchinson melanotic freckle and Behavior Code	87
hyperbaric oxygen	178
hyperthermia as "other" therapy	178
ICD-O-1 coding book as reference	5
ICD-O-2 and ICD-O-3 conversion	88
ICD-O-2 coding book as reference	5
ICD-O-2 vs. ICD-O-3 reportability	28
ICD-O-3 Behavior Code	85-88
ICD-O-3 Histologic Type Code	79-84
"III", etc. as generation identifiers	40
ill-defined primary site and Tumor Size	104
ill-defined primary sites C76. _	73
imaging and Diagnostic Confirmation	107
Imaging, Diagnostic, Narrative	146
immunoglobulin, iodine-labeled	167
Immunophenotype Code	89, 91
immunotherapy	167, 176-177
Immunotherapy -- At This Facility	177
Immunotherapy -- Date Started	177

INDEX

I-12

	<u>page(s)</u>
Immunotherapy -- Narrative	177
Immunotherapy -- Summary	177
immunotherapy agents	176
immunotherapy drugs	176
"impending perforation" and Summary Stage	133
"impinging" and Summary Stage	133
implants, radioactive	166
"imposing" and Summary Stage	133
<i>in situ</i> behavior, terms indicating	86, 87
<i>in situ</i> cases, reportability	9, 18, 85
<i>in situ</i> lesions and Grade Code	90
<i>in situ</i> lesions and Tumor Size	102
<i>in situ</i> Summary Stage , terms indicating	135
<i>in situ</i> tumor and TNM staging	109, 121, 122
<i>in utero</i> case and Date of Diagnosis	94
"incipient invasion" and Summary Stage	133
incisional biopsy and DX/Stg/Pall Proc	153
"induration" and Summary Stage	133
industry and occupation	66-69
inflammatory carcinoma and Tumor Size	103
"infringe" and Summary Stage	133
initial, middle, patient's	41
initial, used with a middle name	41
Institution Referred From	98
Institution Referred To	99
insurance, Primary Payer at Diagnosis	37
"intermediate grade" lymphoma and Grade Code	91
interstitial radiation	166
"into" and Summary Stage	133
intraductal carcinoma and Paget disease of breast	20
intraepithelial neoplasia, anal, case reportability	9, 85
intraepithelial neoplasia, cervical, case reportability	9, 85
intraepithelial neoplasia, prostatic, case reportability	9, 85
intraepithelial neoplasia, vaginal, case reportability	9, 85
intraepithelial neoplasia, vulvar, case reportability	9, 85
intraoperative radiation	168
"intrude" and Summary Stage	133

INDEX

I-13

	<u>page(s)</u>
"invasion" and Summary Stage	133
"invasion into", "onto", "out onto", or "to" and Summary Stage	133
iodine-labeled immunoglobulin.....	167
Iscador.....	178
"Jr" (Junior) as generation identifier	40
Kaposi sarcoma and Tumor Size	100, 104
Kaposi sarcoma, Primary Site Code	20, 73
Kaposi sarcoma, single-vs-multiple primaries	20
"kisses" and Summary Stage	133
Krebiozen.....	1782
laboratory test and Diagnostic Confirmation	107
laboratory test Narrative	146
Laetrile.....	178
laryngopharynx, Primary Site Code change.....	71
Last Contact, Date of	7, 181
Last Name, Patient	7, 40-41
Laterality	7, 76-77
Laterality and Primary Site Narrative	78
laterality and single-vs-multiple primaries	19
LCIS (lobular carcinoma <i>in situ</i>).....	11
legislation, MCR.....	1, 2
lentigo maligna and Behavior Code	87
Letterer-Siwe disease and Tumor Size	104
Leucovorin	171, 178
leukemia and Diagnostic Confirmation	106
leukemia and first course of treatment	150
leukemia and Primary Site Code	73, 80-81
leukemia and Regional Nodes Examined	142
leukemia and Regional Nodes Positive	144
leukemia and single-vs-multiple primaries	insert, 21-27
leukemia and Summary Stage	138
leukemia and Tumor Size	104
leukemia, Immunophenotype Code	91
leukemia, Primary Site Code	73, 80-81
leukemias and lymphomas cross-indexed in ICD-O-3	80-81
linitis plastica and Tumor Size	103
lobular, duct and other carcinomas of breast.....	19

INDEX

I-14

	<u>page(s)</u>
lobular and duct carcinomas of breast, and Primary Site Code	73
lobular carcinoma <i>in situ</i>	11
lobular neoplasia and Behavior Code	87
localized Summary Stage	135
"low grade" lymphoma and Grade Code	89, 91
low malignant potential, case reportability	9, 85
lung cancer and Tumor Size	103
lung cancer, occult, and TNM staging	112, 113, 120, 129
lymph node aspiration and Scope of Regional Lymph Node Surgery	160
lymph node, extension of primary tumor into, and TNM staging	114, 124
lymph node involvement and Summary Stage	133, 136-137
Lymph Nodes Removed, Regional, Number of	161-162
lymph nodes, bilateral involvement, and Summary Stage	137
"lymphadenopathy" and Summary Stage	137
lymphatic diseases and single-vs-multiple primaries	insert, 21-27
lymphatic invasion and TNM staging, not coded	110
lymphoma and Regional Nodes Examined	142
lymphoma and Number of Regional Lymph Nodes Removed	161
lymphoma and Regional Nodes Positive	144
lymphoma and single-vs-multiple primaries	insert, 21-27
lymphoma and Tumor Size	100, 104
lymphoma, Immunophenotype Code	91
lymphoma, Histologic Type Code	80-81
lymphoma, Primary Site Code	73, 80-81
lymphomas and leukemias cross-indexed in ICD-O-3	80-81
lymphoproliferative malignancy, lymphoreticular process, and Primary Site Code	74
lymphoreticular process malignancy and Primary Site Code	74
magnetic resonance imaging and Diagnostic Confirmation	107
magnetic resonance imaging and Grade Code	92
Maiden Name	41
maiden name, Spanish/Hispanic	60-64
malignancy, borderline, and Sequence Number	34
malignancy, borderline, case reportability	9, 85
malignancy, low potential for, case reportability	9, 85
malignancy, uncertain, and Sequence Number	34
malignancy, uncertain, case reportability	9, 85
malignant behavior, terms indicating	88

INDEX

I-15

	<u>page(s)</u>
malignant neoplasms, NOS of skin as non-reportable cases	9, 85
malignant tumor, Sequence Number	33
Managing Physician Name	39
manuals, coding.....	5-6
Marital Status at Diagnosis	52
marker study and Diagnostic Confirmation	107
"mass in the mediastinum", lymph nodes, and Summary Stage	137
"mass in the mesentery", lymph nodes, and Summary Stage	137
"mass in the retroperitoneum", lymph nodes, and Summary Stage	137
Massachusetts Cancer Registry established	1
Massachusetts Cancer Registry, purposes.....	1
"matrix rule", ICD-O.....	9, 86
"matted" and Summary Stage	133
MCR Cancer Patient Abstract (paper form)	4
MCR Facility Code	31, 32
MCR time period for reporting	3
Medicaid, Primary Payer at Diagnosis	37
Medical Record Number	7, 38
Medicare claim number.....	46
Medicare, Primary Payer at Diagnosis	37
melanoma and Tumor Size	105
melanoma, Primary Site Code	74
melanosis, precancerous, and Behavior Code	87
meninges cases, reportability.....	9, 11-12, 85
"metastasis" and Summary Stage	136
metastatic lesions, vs. primary	14, 73
metastatic site and Behavior Code	86
metastatic site and Diagnostic Confirmation	106
metastatic site and Grade/Differentiation/Immunophenotype Code	90
metastatic sites and Staging Narratives	118, 126
metastatic sites and Primary Site Code	73
metastatic sites and TNM staging, not coded	118, 126
metastatic Summary Stage	137-138
metastatic-vs-primary site.....	14, 73
"microinvasive" and Behavior Code	88
microinvasive squamous cell carcinoma and Behavior Code	88
microinvasive squamous cell carcinoma and Summary Stage	135

INDEX

I-16

	<u>page(s)</u>
"microinvasive" and Summary Stage	135
microscopic confirmation and Diagnostic Confirmation	106
middle name and first initial	41
Middle Name, Patient	7, 41
"middle of year" and Date of Diagnosis	95
midline tumor and Laterality	76
midline tumor and Summary Stage	137
MOPP + Prednisone	173
"most likely" and case reportability	10
"most likely" and Summary Stage	133
MRI and Diagnostic Confirmation	107
MRI results and Grade Code	92
multimodality therapy prefix and TNM staging, not coded	110
multiple myeloma and Diagnostic Confirmation	107
multiple myeloma and Regional Nodes Examined	142
multiple myeloma and Regional Nodes Positive	144
multiple myeloma and Summary Stage	138
multiple myeloma and Tumor Size	104
multiple primaries	14-27, 35, 82-84
multiple primaries and Comments/Narrative Remarks	35, 111, 182
multiple primaries and Surgery of Primary Site	158
multiple surgical procedures and Surgery of Primary Site	158
multiple surgical procedures and Surgery -- Narrative	158, 159
multiple tumors and cT Element	111
multiple tumors and Text -- Staging	111, 147
multiple tumors and pT Element	111, 121
multiple tumors and TNM staging, suffix not coded	110, 121
multiple tumors in one organ, and Primary Site Code	71
mycosis fungoides and Tumor Size	100, 104
myeloid sarcoma and Primary Site Code	73
myeloma, multiple and Regional Nodes Examined	142
myeloma, multiple and Regional Nodes Positive	144
myeloma, multiple and Tumor Size	104
myeloproliferative malignancy, lymphoreticular process, Primary Site Code	74
NAACCR Versions 9, 9.1	i, 4
name, "also known as"	42
Name, Alias	42

INDEX

I-17

	<u>page(s)</u>
name, first initial plus middle name	41
Name, Maiden	41
Name of Vendor	183
Name, Patient	7, 40-42
Name, Patient and changes/case deletion	4
name, physician's	39
Name Suffix	40
Narrative Diagnostic Procedures	145-147
Narrative Histology/Behavior/Grade	94
Narrative Primary Site	78
Narrative Remarks	182
Narrative Staging.....	145-147
Narrative Staging and multiple tumors	147
Narrative Staging and site(s) of distant metastasis	118, 126
Narrative, Chemotherapy	172
Narrative, Hormone Therapy	175
Narrative, Immunotherapy	177
Narrative, Other Cancer-Directed Therapy	178, 180
Narrative , patient history and physical examination.....	145
Narrative, Radiation Therapy	168
Narrative, Surgery	159
narrative, DX/Stg/Pall Proc	155
National Cancer Registries Amendment Act	1
neck dissection and Scope of Regional Lymph Node Surgery	160
negative biopsy, positive cytology and reportability	29
neoplasia, intraepithelial, case reportability.....	9, 85
neoplasia, lobular and Behavior Code	87
nephroblastomas, bilateral and Laterality	19
nephroblastomas, bilateral and single-vs.-multiple primaries	19
Neupogen.....	176, 178
neuroblastoma, Primary Site Code	74
nickname	42
no Surgery and Scope of Regional Lymph Node Surgery	160
no Surgery and Surgery -- Narrative	159
No Surgery, Reason For	160, 165
no primary tumor and Tumor Size	104
"no treatment" as treatment plan	149

INDEX

I-18

	<u>page(s)</u>
nodule, tumor, coded in N Element	114, 124
nodule, tumor, coded in T Element.....	111, 121
nodule, tumor, counted in Regional Nodes Examined	142
nodule, tumor, counted in Regional Nodes Positive	143
non cancer-directed surgery (DX/Stg/Pall Proc).....	150, 153-155
"non cancer-directed treatment" (diagnostic, staging, palliative procedures) defined.....	150
non-Hodgkin lymphoma and Tumor Size	104
non-hospital case reporting	1
non-Massachusetts residents, reporting	3
non-reportable cases for Massachusetts Cancer Registry	3, 9, 14, 85
nonanalytic case and Class of Case	3, 7, 96
nonanalytic cases, reporting requirements.....	3, 7
nonmalignant tumor, Sequence Number	34
"NOS" histology code.....	18, 22, 82, 83, 84
"NOS" subcategory, Primary Site Code	71, 73
Nottingham grading and Grade Code	93
nuclear grade.....	89
Number of Regional Lymph Nodes Removed	160, 161-162
Number of Regional Lymph Nodes Removed -- At This Facility	162
Number of Regional Lymph Nodes Removed -- Summary	162
Number of Regional Lymph Nodes Removed and Regional Nodes Examined	142, 161
Number of Regional Lymph Nodes Removed and Regional Nodes Positive	142
observation as Other Cancer-Directed Treatment	179
occult lung cancer and TNM staging	112, 113, 120, 129
occupation and industry	66-69
office, physician's, chemotherapy in.....	172
office, physician's, hormone therapy in.....	175
office, physician's, immunotherapy in	177
office, physician's, lymph nodes removed in.....	161
office, physician's, "other" therapy in.....	180
office, physician's, radiation in.....	167
office, physician's, surgery in	163
"onto" and Summary Stage	133
operative report title and Surgery code	157
Operative Reports Narrative	146
Other Cancer-Directed Therapy	178-180
Other Cancer-Directed Therapy -- At This Facility	180

INDEX

I-19

	<u>page(s)</u>
Other Cancer-Directed Therapy -- Date Started	180
Other Cancer-Directed Therapy -- Narrative	180
Other Cancer-Directed Therapy -- Summary	180
"other" treatment	178-180
ovarian cystadenoma and Behavior Code	28
ovarian primary, bilateral, Laterality	19, 76
ovary, bilateral involvement, and single-vs-multiple primaries	19
overlapping lesion, Primary Site Code	71
"overstep" and Summary Stage	133
oxygen, hyperbaric	178
Paget disease of breast and intraductal carcinoma	20, 88
Paget disease and Tumor Size	103
paired organs	76-77, Appendix B
paired organs and Laterality	76-78
paired organs and single-vs-multiple primaries	19
paired primary sites	76-77, Appendix B
paired primary sites and Laterality	76
palliative treatment	150
"palpable", lymph nodes, and Summary Stage	137
palpitation and Diagnostic Confirmation	107
papillary carcinomas of skin as non-reportable cases	9, 85
paracentesis and DX/Stg/Pall Proc	153
pathologic confirmation of diagnosis and case reportability	10
pathologic M Element	126-127
pathologic N Element	124-125
pathologic Stage Grouping	128-129
pathologic staging, TNM	109, 110, 121-129
pathologic T Element	121-123
pathology report terminology and case reportability	10
pathology report Narrative	147
pathology-only cases, reportability	29
patient confidentiality	2
Patient First Name	41
patient history and physical exam Narrative	145
Patient Last Name	40
Patient Middle Name	41
Patient Name	40-42

INDEX

I-20

	<u>page(s)</u>
Patient Name, Suffix	40
patient surname	40
Payer, Primary, at Diagnosis	37
Pediatric Stage	139-140
Pediatric Staging System	140, 141
penis, skin of, case reportability	9, 85
PET results and Grade Code	91
phlebotomy as Other Cancer-Directed Treatment	179
physical exam Narrative	145
Physician Name, Managing	39
physician's office, chemotherapy in.....	172
physician's office, hormone therapy in	175
physician's office, immunotherapy in	177
physician's office, lymph nodes removed in.....	161
physician's office, "other" therapy in.....	180
physician's office, radiation therapy in	167
physician's office, surgery in	163
physician's office, treatment in, and "at this facility" fields	151
physician, managing.....	39
pilocytic astrocytoma and behavior	28, 86
PIN III, case reportability	9, 85
pineal gland and case reportability	9, 85
pituitary gland and case reportability	9, 85
Place of Birth	45, Appendix A
Place of Birth and Race	55-59
Place of Death	182, Appendix A
Place of Death and living patient	182
plan, treatment.....	149, 150
pM.....	126-127
pN	124-125
pN and Regional Nodes Examined	142
pN and Regional Nodes Positive	143
polyposis, familial, and Primary Site Code	15-16, 73
polyposis, familial, and single-vs.-multiple primaries	15-16
polyposis, familial, and Tumor Size	103
positron emission tomography and Grade Code	92
"possible" and case reportability.....	10

INDEX

I-21

	<u>page(s)</u>
"possible" and Summary Stage	133
Postal Code at Diagnosis	51
"potentially" and case reportability	10
PPO, Primary Payer at Diagnosis	37
pre-2001 cases, coding	i
precancerous melanosis and Behavior Code	87
Prednisone with Chemotherapy (MOPP, COPP)	171, 173
"predominantly" and Histologic Type Code	83
prefixes and Primary Site Code	74
prefixes, TNM staging, not coded	110
pre-invasive cervical neoplasia	9
preoperative Chemotherapy and TNM staging	110
preoperative Radiation and TNM staging	110
preoperative Radiation and Tumor Size	100
preoperative treatment and Regional Nodes Examined	142
preoperative treatment and Regional Nodes Positive	144
prepuce, skin of, case reportability	9, 85
"presumed" and case reportability	10
"presumed" and Summary Stage	133
Primary Payer at Diagnosis	37
Primary Site and case reportability	9, 11, 85
Primary Site Code	7, 71-75
primary site codes considered a single site	15, 17
primary site groupings for single-vs-multiple primaries	15, 17
Primary Site, Narrative	78
Primary Site Narrative and Laterality	78
Primary Site Narrative and multiple tumors	111
primary-vs-metastatic lesions	14
primary-vs-metastatic site	14, 73, 78
priority of codes, Surgery of Primary Site	157
"probable" and case reportability	10
"probable" and Summary Stage	133
prophylactic radiation	166
prostate cancer and Diagnostic Confirmation	107
prostate cancer and endocrine surgery/radiation	174
prostate cancer and Grade Code	93
prostate, intraepithelial neoplasia of, and Behavior Code	85

INDEX

I-22

	<u>page(s)</u>
prostate, intraepithelial neoplasia of, case reportability.....	9, 85
prostate, transurethral resection and Tumor Size	104
prostatic intraepithelial neoplasia and Behavior Code	85
protocol number, Chemotherapy	169, 172
"protruding into" and Summary Stage	133
province at diagnosis (Canada).....	49, 50
PSA test and Diagnostic Confirmation	107
pseudo-topographic morphology terms.....	72
pStage Grouping.....	128-129
pT.....	121-123
pTNM.....	110, 121-127-123
purposes of the MCR.....	1
"questionable" and case reportability.....	10
"questionable" and Summary Stage	133
Queyrat erythroplasia and Behavior Code	87
Race	7, 53-59
Race and Birthplace	55-59
Race 1	55
Race 2	56
Race 3	57
Race 4	58
Race 5	59
Radiation Therapy	166-168
Radiation Therapy -- At This Facility	167
Radiation Therapy -- Date Started	168
Radiation, beam, types of	166
Radiation, curative	166
Radiation, hormonal.....	166, 173
Radiation, intracavitary.....	167
Radiation, intravenous.....	167
Radiation, oral.....	167
Radiation, prophylactic	166
Radiation/Surgery Sequence	168
Radiation Therapy and cancer-directed Surgery.....	168
Radiation Therapy, external source.....	166
Radiation Therapy, internal source.....	166, 167
Radiation Therapy -- Narrative	168

INDEX

I-23

	<u>page(s)</u>
Radiation Therapy, radioactive substances for.....	166
Radiation Therapy -- Summary	167
radioactive implants / seed implants.....	166
radioactive substances for radiation therapy	166
radiography and Diagnostic Confirmation	107
radioisotope, types of	166
radiosurgery.....	166
"reaching out" and Summary Stage	133
re-excision and cancer-directed Surgery	156
Reason For No Surgery	165
"reasonable clinical certainty" of primary site, and TNM staging.....	109
Reconstruction, delayed	164
Reconstruction -- First Course	164, Appendix D
rectum, cancer of, and Tumor Size	103
recurrences not reportable.....	3
recurrent cancer prefix and TNM staging, not coded	110
reference date, Massachusetts Cancer Registry (January 1, 1982)	1, 3
references	5
Regional Lymph Node Surgery, Scope of	160-161
Regional Lymph Nodes Removed, Number of	161-162
Regional Nodes Examined	142-143
Regional Nodes Examined and Number of Regional Lymph Nodes Removed	142, 161
Regional Nodes Positive	143-144
regional Summary Stage	136-137
regulations, confidentiality.....	2
relapse and subsequent treatment	149, 150
Remarks, Narrative	176
replacement therapy, hormone	182
reportability, ICD-O-2 vs. ICD-O-3.....	28
reportability of cases to the Massachusetts Cancer Registry.....	3, 9, 28, 85
"reportable diagnosis"	10, 85
Reporting Facility Code and nonanalytic case reporting.....	7
reporting methods for Massachusetts Cancer Registry	4
reporting on diskette.....	4
reporting requirements for Massachusetts Cancer Registry	1, 3, 9-13, 28, 40
Reporting Source	7, 108
resection, en bloc, of primary and regional tissues, and Surgery of Primary Site	157, 163

INDEX

I-24

	<u>page(s)</u>
resection, transurethral, and DX/Stg/Pall Proc	153
resection, transurethral and Tumor Size	104
residual tumor and cancer-directed Surgery	156
residual tumor prefix and TNM staging, not coded	110
residual tumor and Tumor Size	100
reticuloendothelial system and Primary Site Code	74
reticuloendotheliosis and Tumor Size	104
retinoblastoma, bilateral, and Laterality	19, 76
retinoblastoma, bilateral, and single-vs-multiple primaries.....	19
retroareolar breast tumor, Primary Site Code	73
risk factors and Stage Grouping, and Comments/Narrative Remarks	119, 128, 182
risk factors and Stage Grouping, and Text -- Staging	119, 128, 147
ROADS Manual, as reference.....	5
rTNM.....	110
"rules out" and case reportability	10
"rules out" and Summary Stage	133
"S", lymphoma suffix, and TNM staging, not collected	120, 129
"Saint", abbreviating in Last Name	40
sarcoma, myeloid and Primary Site Code	73
sarcoma, Kaposi and Primary Site Code	73
sarcoma, Kaposi, and Tumor Size	100, 104
sarcoma, Kaposi, and single-vs-multiple primaries.....	20
scan Narrative	146
Scarff Bloom-Richardson (SBR) grading and Grade Code	93
scleral invasion and TNM staging, not coded.....	110
scope exam and Narrative	146
Scope of Regional Lymph Node Surgery	160-161
Scope of Regional Lymph Node Surgery and no cancer-directed Surgery	160-161
Scope of Regional Lymph Node Surgery -- At This Facility	161, Appendix D
Scope of Regional Lymph Node Surgery -- Summary	161, Appendix D
scrotum, skin of, case reportability	9, 85
seed implants, radioactive	166
SEER Summary Stage	130-138
SEER manuals as references.....	5-6
<i>Self-Instructional Manuals for Tumor Registrars</i> (SEER)	6
"Senior" as generation identifier	40
Sequence Number -- Hospital	7, 33-35

INDEX

I-25

	<u>page(s)</u>
Sequence Number--Central	35
serum markers and Stage Grouping, and Comments/Narrative Remarks	119, 128, 182
serum markers and Stage Grouping, and Text -- Staging	119, 128, 147
Sex , patient's	7, 51
Sezary disease/syndrome and Tumor Size	100, 104
"shotty", lymph nodes, and Summary Stage	1372
simultaneous diagnoses	15
simultaneous diagnoses and Sequence Number	35
single-vs-multiple primaries	insert, 14-27, 82-84
single-vs-multiple primaries, Histologic Type Code	insert, 16, 21-27, 82-84
"site difference" for single-vs-multiple primaries	15
site groupings considered a single site.....	15, 17
site(s) of distant metastasis and Staging Narratives	118, 126
site(s) of distant metastasis and TNM staging, not coded	118, 126
site-specific morphologies and Primary Site Code	72
site/histology combination, unusual, and Comments/Narrative Remarks	75, 78, 94, 182
site/histology combinations and case reportability.....	9, 12-13, 85
Size of Tumor	100-105
skin epithelial carcinomas, as non-reportable cases	9, 85
skin malignant neoplasms, NOS, as non-reportable cases	9, 85
skin of genital sites, case reportability.....	9, 85
skin, Kaposi sarcoma, and single-vs-multiple primaries.....	20
Smoking Status (Tobacco History).....	65
Social Security Number	7, 46
Social Security Number and changes/case deletion	4
Social Security Number prohibited from release.....	2
software vendor, name	183
Spanish surname	60-64
Spanish/Hispanic Origin	60-64
Spanish/Hispanic Origin and Birthplace	60
specimen size and Tumor Size	101
spelling changes in Patient Name	4
"spring" and Date of Diagnosis	95
squamous cell carcinoma, microinvasive, and Behavior Code	88
squamous cell carcinomas of skin as non-reportable cases	9, 85
squamous intraepithelial neoplasia.....	9
"Sr" (Senior) as generation identifier.....	40

INDEX

I-26

	<u>page(s)</u>
"St", as abbreviation for Saint in Last Name	40
"Stage 0" and Behavior Code	87
staging and Behavior differences.....	88
Staging Narratives.....	110, 111, 118, 121, 126, 145-147
Staging Narratives and multiple tumors.....	111, 147
Staging Narratives and site(s) of distant metastasis.....	118, 126
Staging Text (other).....	147
start dates, treatment.....	151
State at Diagnosis	49-51
stem cell transplant.....	176
stereotactic radiosurgery.....	166
steroid therapy.....	173-175
stomach cancer and Tumor Size	103
Street Address at Diagnosis	48
subareolar breast tumor, Primary Site Code	73
subsequent therapy.....	149, 150, 170
Suffix, Name	40
suffixes, TNM staging, not coded.....	110
"suggests" and case reportability.....	10
"suggests" and Summary Stage	133
Summary Stage	130-138
summary, treatment, fields.....	151
supportive care as Other Cancer-Directed Treatment	179
Surgery -- Narrative	159
Surgery -- Narrative and DX/Stg/Pall Proc	154, 155
Surgery -- Narrative and multiple surgical procedures.....	158, 159
Surgery -- Narrative and no Surgery.....	143, 151
Surgery of Other Regional Sites, Distant Sites or Distant Lymph Nodes	157, 160, 163
Surgery of Other Regional Sites, Distant Sites or Distant Lymph Nodes--Summary ..	163, Appendix D
Surgery of Other Regional Sites, Distant Sites or Distant Lymph Nodes--At This Facility	163, Appendix D
Surgery of Primary Site	157-159
Surgery of Primary Site and multiple primaries.....	158
Surgery of Primary Site and multiple procedures.....	158, 159
Surgery of Primary Site and Number of Regional Lymph Nodes Removed	161
Surgery of Primary Site -- At This Facility	159, 162, Appendix D
Surgery of Primary Site , code priority.....	157

INDEX

I-27

	<u>page(s)</u>
Surgery of Primary Site -- Date Started	159
Surgery of Primary Site -- Summary	158, 162, Appendix D
Surgery/Radiation Sequence	168
surgery reports Narrative (staging)	146
surname, patient's	40
surname, Spanish/Hispanic	60-64
"suspect/ed" and case reportability	10
"suspect/ed" and Summary Stage	133
"suspicious" and case reportability	10
"suspicious" and Summary Stage	133
suspicious cytology and case reportability	10
synchronous diagnoses	16
Synthroid	174
systemic disease, Summary Stage	137-138
teletherapy, Radiation Therapy	166
terminology in medical record for non-reportable cases	10
terminology in medical record for reportable cases	10
Text--DX Proc--Lab Tests	146
Text--DX Proc--Op	146
Text--DX Proc--Path	147
Text--DX Proc--PE	145
Text--DX Proc--Scopes	146
Text--DX Proc--X-Ray/Scan	146
Text--Staging	147
Thalidomide	178
thoracentesis and DX/Stg/Pall Proc	153
thyroid cancer and Hormone Therapy	174
thyroid-stimulating hormone	174
time period and first course of treatment	149-150
time periods for reporting to MCR	3
time period for Summary Stage	132
TNM Edition Number	130
TNM staging	109-130
TNM staging books as references	5
"to" and Summary Stage	133
Tobacco History	65
topography (Primary Site) code	71-75

INDEX

I-28

	<u>page(s)</u>
Town at Diagnosis	49
transplant, bone marrow / stem cell	176
transfusion, blood, as Other Cancer-Directed Treatment	179
transurethral resection and DX/Stg/Pall Proc	153
transurethral resection and Tumor Size	104
treatment "at this facility" fields	151
"treatment, first course" defined.....	149-150
treatment narratives	151, 178
treatment plan.....	149
treatment start dates	151
treatment summary fields.....	151
treatment, failed	149, 150
TSH (thyroid-stimulating hormone).....	174
tumor embolization.....	178
tumor nodule coded in N Element	114, 124
tumor nodule coded in T Element.....	111, 121
tumor nodule counted in Regional Nodes Examined	142
tumor nodule counted in Regional Nodes Positive	143
Tumor Size	100-105
TUR as DX/Stg/Pall Proc	153
TUR/TURB/TURP and Tumor Size	104
type of business/usual industry	66-69
Type of Reporting Source	7, 108
"typical of/for" and case reportability	10
ultrasound and Diagnostic Confirmation	107
uncertain Behavior and Grade	91, 92
uncertain Behavior, Sequence Number	34
uncertain malignancy cases, reportability	9, 11, 85
uninsured patient, Primary Payer at Diagnosis	37
unknown primary site.....	74
unknown primary site and Comments/Narrative Remarks	78
unknown primary site and extranodal lymphoma	74
unknown primary site and Grade/Differentiation/Immunophenotype Code	90
unknown primary site and Laterality	76
unknown primary site and Number of Regional Lymph Nodes Removed	162
unknown primary site and Regional Nodes Examined	142
unknown primary site and Regional Nodes Positive	144

INDEX

I-29

	<u>page(s)</u>
unknown primary site and Summary Stage	138
unknown primary site and TNM staging	109
unknown primary site and Tumor Size	104
unknown Summary Stage	138
unorthodox treatment.....	178
"up to" and Summary Stage	133
"usual industry" defined	66, 69
"usual occupation" defined	66, 68
"usual residence" address at diagnosis defined.....	47
vagina, intraepithelial neoplasia of, case reportability	9, 85
vagina, skin of, case reportability	9, 85
VAIN III, case reportability.....	9, 85
Vendor Name / Version Number	183
vendors and case reporting.....	4
venous invasion and TNM staging, not coded	110
Versions 9, 9.1	i, 4
"very close to" and Summary Stage	133
VIN III, case reportability	9, 85
"visible swelling", lymph nodes, and Summary Stage	137
visualization and Diagnostic Confirmation	107
Vital Status	181
vulva, intraepithelial neoplasia of, case reportability.....	9, 85
vulva, skin of, case reportability	9, 85
Waldenstrom macroglobulinemia and Diagnostic Confirmation	107
Welfare, Primary Payer at Diagnosis	37
wide excision and cancer-directed Surgery	156
"widespread" and Tumor Size	103
Wilms tumor, bilateral, and single-vs-multiple primaries	19
Wilms tumor, Laterality	76
"winter" and Date of Diagnosis	95
"with features of" and Histologic Type Code	83
"with foci of" and Histologic Type Code	83
"worrisome" and case reportability	10
"worrisome" and Summary Stage	133
X-ray Narrative	146
Year First Seen for This Primary	36
Year First Seen for This Primary and Accession Number	36

INDEX

I-30

	<u>page(s)</u>
Year First Seen for This Primary and diagnosis year.....	36
year of diagnosis and Age at Diagnosis	44
year of diagnosis and case reportability.....	28
year of diagnosis and Year First Seen for This Primary	36
yTNM	110
yTNM and Text -- Staging	147
Zip Code at Diagnosis	51